Company

Novartis

Pharmaceutical intelligence for Novartis with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 5
Assets: 6

Recent signals(5)

CompetitiveJune 18, 2026

First-in-human study of NTSR1-targeted imaging in prostate cancer shows promise

[18F]-AlF-NOTA-neurotensin shows potential as an NTSR1-targeted radiotracer for prostate cancer imaging.

ClinicalJune 18, 2026

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

ClinicalJune 18, 2026

Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment

The CANUT Junior study is assessing sensory changes in pediatric oncology patients, with initial recruitment challenges leading to protocol amendments.

ClinicalJune 17, 2026

R-MVST Cells Show Promise for Treating Refractory Viral Infections

A clinical trial is assessing the safety and feasibility of R-MVST cells for patients with refractory viral infections caused by EBV, CMV, ADV, or BK virus.

CompetitiveJune 17, 2026

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

The Pra-ffd hydrogel demonstrated improved bioavailability and reduced ocular inflammation in preclinical models.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(3)

ClinicalJune 18, 2026

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

ClinicalJune 18, 2026

Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment

The CANUT Junior study is assessing sensory changes in pediatric oncology patients, with initial recruitment challenges leading to protocol amendments.

ClinicalJune 17, 2026

R-MVST Cells Show Promise for Treating Refractory Viral Infections

A clinical trial is assessing the safety and feasibility of R-MVST cells for patients with refractory viral infections caused by EBV, CMV, ADV, or BK virus.